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Karthikeshwar Kasirajan, MD,a and Peter A. Schneider, MD,b Atlanta, Ga; and Honolulu, Hawaii
Background: Recurrent stenotic lesions associated with vein graft bypass grafts are often fibrous and smooth. Unlike de
novo atherosclerotic lesions, they respond poorly to balloon angioplasty, and may often result in a dissection requiring
stent placement to avoid early recurrent thrombosis or open repair of residual stenosis. A novel balloon designed with
three or four longitudinally placed 0.127-mm atherotomes was used at angioplasty to treat focal peripheral vein graft
stenosis, in an attempt to minimize dissection by producing a controlled plaque fracture.
Methods: Over 11 months, patients with focal (<2 cm) peripheral vein graft stenosis underwent cutting balloon
angioplasty (Boston Scientific, San Diego, Calif) at two separate centers. Baseline patient demographic data, type of
bypass, velocity at pre-procedural and post-procedural duplex scanning, procedural results, complications, and type of
long-term anticoagulation were recorded. Follow-up consisted of duplex ultrasound scanning at 1, 3, and 6 months and
every 6 months for 2 years.
Results: The mean age of the patients was 66.8  10 years. No intent to treat failure was noted. In most patients a 4-mm
balloon was used (15 of 19) to treat 10 above-knee vein bypass grafts and 9 below-knee vein bypass grafts. No patient
required placement of a stent or conversion to open surgery because of recoil, dissection, or suboptimal angioplasty. The
mean velocity at pre-procedure duplex scanning at the site of vein graft stenosis was 373  56.8 cm/s, and the mean
velocity post-treatment at 1-month follow-up was 144  50 cm/s. The mean length of stay was 26  32 hours. Overall,
four patients continued to receive warfarin anticoagulation therapy, in addition to aspirin. During a mean follow-up of
11.4 7 months, recurrent stenosis developed in one patient. No other complications or graft recurrent thrombosis was
noted.
Conclusion: Cutting balloon angioplasty may help overcome hoop stress early, by producing a controlled, longitudinal
neointimal lesion laceration and thereby facilitating a fracture line along predetermined microincisions. Our study results
demonstrate acceptable early outcomes, with no requirement for bail-out stenting or open surgery. (J Vasc Surg 2004;
39:702-8.)Vein bypass grafts are currently considered the most
durable and effective for limb salvage in patients with
limb-threatening lower extremity ischemia.1,2 However,
vein bypass grafts may develop stenotic lesions and
thrombosis over time. Surveillance programs improve
the long-term graft patency and limb salvage by as much
as 10% to 15%, and revision of stenosis identified at
duplex scanning is significantly less expensive and more
successful than revision after graft thrombosis.3 Since the
initial serial angiographic surveillance by Szilagyi et al,4 it
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doi:10.1016/j.jvs.2003.10.046702has been adequately demonstrated that intrinsic vein
graft stenosis is the most likely culprit for occlusion 30
days to 5 years after vein graft implantation. The vast
majority of these graft-threatening lesions are focal, and
their prompt correction returns the patency curve to that
of a graft in which stenosis has never developed.5 How-
ever, if graft thrombectomy or lysis was required before
identification of the culprit stenosis, the 1-year patency
rate was a dismal 20% to 35%.6-8
Numerous studies have demonstrated the efficacy
and durability of open surgical repair in the treatment of
infrainguinal vein bypass graft stenosis.6,9 However,
open surgical correction of these lesions is not always
straightforward, and may require complex reconstruc-
tive techniques to maintain graft patency and limb sal-
vage. The use of percutaneous methods of treating vein
graft stenosis has resulted in varying outcomes, and the
role of percutaneous angioplasty (PTA) to treat focal
vein graft stenosis has not yet been defined. We report
the use of a novel balloon for the treatment of focal vein
graft stenosis.
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Data were prospectively entered into a computer data
base, and supplemented with chart reviews when required.
Patients with a vein bypass graft stenosis, as defined with
duplex criteria,10 were offered diagnostic angiography and
possible PTA. Cutting balloon PTA was restricted to le-
sions less than 2 cm long and vein grafts with a duplex scan
diameter of at least 3 mm in the segment with stenosis.
Data collected included patient demographics, type of vein
bypass, indications for bypass, status of inflow and outflow
vessels, time to stenosis after the initial bypass procedure,
pre-procedure and post- procedure anticoagulation ther-
apy, velocity at pre-procedure and post-procedure duplex
scanning, maximum balloon diameter, complications, and
recurrent stenosis or thrombosis of the treated conduit.
Device description. The cutting balloon has currently
been approved for angioplasty of coronary de novo resistant
lesions. Hence it is designed with coronary specifications.
The balloon has 3 to 4 atherotomes, with a height equiva-
lent to that of a coronary strut (0.005 inches [0.127 mm]).
The length of the atherotome is 15 mm, and the length of
the balloon is 18 mm (Fig 1). The base of the atherotome
has T notches, to increase flexibility during balloon passage.
The metal atherotome is bonded to a mounting pad, and
the mounting pad plus atherotome is then “glued” to the
surface of the balloon and is exposed only during balloon
inflation. The balloon is made of a noncompliant polyeth-
ylene therephthalate material with a nominal pressure of 6
atm and a rated burst pressure of 10 atm. The balloon is
available in diameters ranging from 2 to 4 mm, with a
crossing profile of 0.041 to 0.046 inches (1.04-1.16 mm).
The catheter is a monorail system, with the distal part
enabling rapid exchange over a standard 0.014-inch guide
wire.
Technique of balloon angioplasty. Access was rou-
tinely obtained through a contralateral femoral puncture.
An initial aortoiliac angiogram was obtained to exclude an
inflow lesion. Selective cannulation of the contralateral
common femoral artery was then performed, followed by
placement of a 6F up-and-over sheath (Pinnacle Destina-
tion; Boston Scientific, Maple Grove, Minn). The vein
bypass graft and outflow vessels were imaged before angio-
plasty of the vein graft stenosis. All patients were given
5000 IU of intravenous heparin during the intervention,
and had been taking oral aspirin for a minimum of 1 week
before the procedure. Once the culprit lesion was identi-
fied, it was crossed with a 0.014-inch guide wire, followed
by a cutting balloon of adequate diameter. Only lesions less
than 2 cm long were treated with this technique. The
balloon was inflated slowly, enabling the balloon and athe-
rotome to open completely. The balloon was then deflated
and reinflated at least once more. A completion angiogram
of the treatment zone and the outflow vessels was obtained.
Surveillance after cutting balloon angioplasty. An
initial duplex scan is obtained at the first clinic visit (1
month) after PTA. Subsequent clinic visits and studies were
planned for 3 months and then every 6 months for 2 years.Annual studies are to be obtained for the lifetime of the
patient or graft. A peak systolic velocity (PSV) greater than
300 cm/s or a PSV that is three and one-half times that of
an adjacent normal segment would be considered highly
indicative of a vein graft stenosis. If progressive increase in
the PSV is noted in the treatment zone, but not reaching
the revision threshold, the studies would be repeated every
2 months until the lesion resolves or progresses to the point
of requiring revision.
RESULTS
Overall, 19 consecutive patients with focal vein graft
stenosis received treatment over 11 months. Three addi-
tional patients with diffuse vein graft stenosis underwent
surgical revision (patch in 1 patient, replacement vein graft
in 2 patients) during the same study period. Although this
was not a prospective study, all focal vein graft stenosis seen
by the two physicians over the 11 months were successfully
treated with the cutting balloon; hence there was no intent-
to-treat failure. All treated conduits were vein bypass grafts.
Overall, 10 bypass grafts were in the above-knee location,
and 9 were to a below-knee target vessel (4 below-knee
popliteal, 5 tibial or peroneal). All above-knee bypass grafts
were reversed, and 2 of the below-knee bypass grafts were
in situ saphenous vein grafts. Four of the above-knee bypass
graft procedures were performed to treat claudication, and
the others were for limb salvage. The average time to
stenosis in the above-knee bypass grafts was 17.4  18.2
months (range, 3-63 months), and in the below-knee
bypass grafts was 12.5  16.4 months (range, 1-54
months). Sites of stenosis included the proximal anastamo-
sis in 9 patients, mid-graft in 7 patients, and distal location
in 3 others. The maximum balloon diameter used was 4
mm in 15 grafts, and a 3-mm or 3.5–mm balloon was used
in the other 4 grafts. We were able to achieve an angio-
graphic stenosis of less than 10% in all patients after cutting
balloon PTA. No local or systemic complications were
noted. All patients were given aspirin therapy before and
after the procedure, and 4 patients continued to receive
warfarin anticoagulation therapy for other systemic reasons.
The mean duration of hospital stay was 26  32 hours. All
but 1 patient not receiving warfarin was sent home the same
day. The mean velocity at pre-procedure and post-proce-
dure duplex scanning is presented in the Table I, along with
patient demographic data.
Fig 1. Cutting balloon with longitudinally molded atherotomes.
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April 2004704 Kasirajan and SchneiderFig 2. Pre-procedure (A) and post-procedure (B) cutting balloon angioplasty of proximal vein graft stenosis. Note
highly calcified superficial femoral artery (arrows). Velocity at duplex scanning, 402/99 (ankle-brachial index, 0.99).
Pre-procedure (C) and post-procedure (D) intravascular ultrasound images of cutting balloon angioplasty demonstrate
excellent luminal restoration. However, the patient continued to have elevated flow at duplex scanning (374/87;
ankle-brachial index, 0.98).
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the origin of the saphenous vein graft from the superficial
femoral artery had persistent elevation in velocity at duplex
scanning at the 1-month visit. This patient had a highly
calcified superficial femoral artery, and despite the excellent
angiographic and intravascular ultrasound images (Fig 2,
A-D) at cutting balloon angioplasty, did not demonstrate a
significant decrease in velocity at the 1-month duplex scan-
ning examination. The patient opted for an open surgical
revision during the follow-up clinical visit. Because of the
extensive amount of calcification seen in the inflow vessel
(superficial femoral artery), a jump graft was performed
from the common femoral artery to the proximal portion of
the saphenous vein bypass graft. A repeat angiogram was
not obtained before revision; hence the specific cause for
failure could not be established with certainty. During a
mean follow-up of 11.4  7 months, no other recurrence
was observed, and there was no graft occlusion. Velocity at
duplex scanning in all other patients during follow-up
showed no significant change; all 19 patients underwent
duplex scanning at 3 months.
DISCUSSION
The major limiting factor for long-term patency of vein
bypass grafts is recurrent stenosis. The short-term risk for
graft occlusion in the presence of an unrevised critical
stenosis is nearly 80%.11 The method of choice (open
surgery vs PTA) for treatment of the culprit lesions contin-
ues to remain controversial. Perler et al12 reported an
experience consisting of 24 instances of PTA in 37 individ-
ual vein graft stenoses in 19 grafts. This series excluded all
those grafts that required initial thrombolysis. Recurrent
lesions occurred in 67% of grafts. The 3-year primary pa-
tency rate was 22%, and repeat PTA provided little addi-
tional benefit, so the secondary patency rate remained
limited to 27%. Similarly, Sheridan et al13 detected 22 vein
graft stenoses in a group of 175 monitored grafts. Inter-
vention with PTA or surgical revision was initially successful
in all lesions. Within 6 months, however, 15 of 16 stenoses
managed with angioplasty recurred, whereas 5 of the 6
surgical revisions remained patent. Bandyk et al14 reported
their results with secondary intervention for infrainguinal
vein graft failure, and demonstrated that long-term dura-
bility was clearly superior with surgical revision, especially if
the stenotic segment was completely excised and replaced
with a short interposition vein graft. Whittemore et al15
used PTA in 30 patients with 54 stenotic lesions in autog-
enous vein grafts after infrainguinal reconstruction. The
5-year primary patency rate was 18%, with no significant
differences observed among patency rates on the basis of
initial indication, length of stenotic lesion, or requirement
for preliminary thrombolytic therapy. They demonstrated
that the 3-year patency rate associated with vein graft
lesions requiring only a single angioplasty procedure were
significantly higher (59%) than those requiring repetitive
dilation (6%). However, when PTA was used selectively,
the outcome was similar to that with open surgical repair
(63% vs 63% at 2 years).16 Of interest, fewer graft failuresoccurred in the PTA group compared with the open surgi-
cal group, although the repeat intervention rate for PTA
was higher. In another report of single lesions less than 1.5
cm long with grafts more than 3.0 mm in diameter PTA
yielded reasonable results.17 In the authors’ experience, use
of standard balloons to treat peripheral vein grafts resulted
in about a 20% incidence of requirement for bail-out stent-
ing, with a primary patency rate of about 40% at 1 year.
However, the final role of PTA versus open surgical revision
continues to remain a topic of controversy, and no consen-
sus is currently available.
When operations are performed to treat recurrent ste-
nosis, the lesions typically are pale, firm, and rubbery at
gross inspection. The cellular component of these neointi-
mal lesions is thought to be primarily smooth muscle cells
that have proliferated and migrated from the media.18 The
fibrous nature of these lesions may make them less respon-
sive to PTA, as opposed to de novo atherosclerotic lesions.
Significantly higher pressure may be required to dilate these
fibrous lesions, often resulting in areas of extensive dissec-
tion or rupture from the hoop stress being reflected to the
adjacent nonstenotic region. This may be overcome by
controlled and localized areas of microincisions with the
cutting balloon, sparing the interincisional segments. Ani-
mal experiments have demonstrated that cutting balloons
can minimize the vessel wall response to injury, which may
be ultimately responsible for the series of cellular and
subcellular events leading to myointimal hyperplasia and
recurrent stenosis.19,20 Coronary data have been contro-
versial with the use of the cutting balloon. However, in
many of the coronary studies, the cutting balloon was used
primarily to treat de novo atherosclerotic lesions. In a
recent study involving 1238 lesions, the use of the cutting
balloon did not reduce the rate of recurrent stenosis, com-
pared with conventional balloon PTA.21 These authors
concluded that cutting balloons should be reserved for
resistant lesions and in-stent recurrent stenotic lesions.21
This was further demonstrated by studies involving the use
of cutting balloons for treatment of neointimal hyperpla-
sia.22,23
Our study was based on this concept of using cutting
balloon technology to treat focal vein grafts with a diameter
Patient demographic data
Above-knee
(n  10)
Below-knee
(n  9)
Male patients 7 4
Mean age (y) 66  10 67  11
Diabetes 3 4
Coronary artery disease 4 4
Hypertension 6 5
Smoking 6 3
Pre-duplex velocity 364  62 382  53
Post-duplex velocity 136  39 153  61†
*Given in cm/s at 1-month follow-up.
†One patient with persistent elevated velocity at 1-month visit is not in-
cluded.
JOURNAL OF VASCULAR SURGERY
April 2004706 Kasirajan and Schneidergreater than 3 mm. Engelke et al24 evaluated the use of
cutting balloon PTA to treat peripheral vein graft stenosis
in 15 patients. No local patient-related complications were
reported, and at a mean follow-up of 10 months only two
recurrent stenoses were observed. We were able to achieve
similar results with focal lesions in optimal diameter con-
duits. In our report the single recurrence was seen in a
lesion with extensive inflow vessel calcification. Despite the
shortcomings of a small sample size in our observational
study, the results are superior to published data on conven-
tional PTA to treat vein graft stenosis, and compare favor-
ably with open surgical revision.
In conclusion, cutting balloon PTA is a useful endovas-
cular tool in patients with recurrent stenosis. Further pro-
spective randomized trails are required to establish its role
in the routine treatment of neointimal lesions.
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Submitted Sep 14, 2003; accepted Oct 14, 2003.DISCUSSIONDr Douglas Hood (Los Angeles, Calif). Drs Kasirajan and
Schneider present a retrospective study of 19 focal vein graft
stenoses treated with cutting balloon angioplasty with excellent
results, with restenosis at the treated site occurring in only one
patient with a mean follow-up of 11.4  7 months. They tell us
that all vein stenoses of a2 cm in length seen by the two authors
during the study period were treated with this technique, presum-
ably eliminating selection bias for the study. Data from the study
was prospectively collected. However, no control group of patients
who had undergone alternative treatment methods such as plain
old balloon angioplasty or surgical graft revision was included for
comparison. Thus, no definitive conclusions regarding the role of
this technique in the treatment of vein graft stenosis can be made.This report tells us that cutting balloon angioplasty can be per-
formed, but does not tell us that it should be performed.
There are, of course, a number of potential attractive features
of the endovascular management of vein graft stenosis. Not the
least of these is the avoidance of a surgical incision in a reoperative
field, which has a higher risk of infection and failure of primary
wound healing, and avoidance of the need to identify a suitable
segment of autogenous vein for use as a patch or interposition
graft.
Our experience with endovascular management of vein graft
stenosis due to intimal hyperplasia has been less than optimal, as
demonstrated in a report recently published in the Archives of
Surgery by Steve Katz, a member of our group. The failure rate at
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this reason, balloon angioplasty has not been a preferred technique
for the management of this problem, and we have relied on open
surgical methods of correction.
Cutting balloons are approved and marketed for use in the
coronary arteries, but of course may have additional uses in the
peripheral circulation. I have seen a few case reports of the success-
ful use of these balloons for dialysis access stenosis, the pathology
of which (intimal hyperplasia occurring within a segment of vein) is
similar to the vein graft stenoses described in this report. This is the
first report I have seen of the use of cutting balloons for the
treatment of peripheral venous bypass graft stenosis.
I have both technical and methodological questions for the
authors. First, it is frequently recommended in the literature con-
cerning dialysis access stenosis that prolonged balloon inflation
times be used in an effort to overcome the elastic recoil of these
fibrous lesions. What is your standard inflation time and your
standard inflation pressures in the treatment of these cases?
During insertion, the blades on a fresh balloon are well pro-
tected within the folds of the balloon as you described, but the
blades may remain exposed after balloon deflation. Is this of clinical
concern? Is there any potential for vessel injury by the blades
during balloon removal and are there any special techniques that
we need to know to rewrap this balloon and recover those blades?
It is interesting that approximately one-half of stenoses in this
report were anastomotic. Do you have any concerns about dilating
anastomotic strictures and, in particular, would you recommend
waiting a specific minimum amount of time before using a cutting
balloon on an anastomosis?
Regarding follow-up, were these data subjected to life table
analysis with estimation of standard errors? Mean follow-up in the
study was 11 months, but what was the median? Is the longevity of
follow-up misrepresented by a few patients with prolonged fol-
low-up and only a few months’ follow-up in the majority?
And lastly, do you envision any other specific role for this
technology in the management of peripheral vascular disease?
I congratulate the authors on a well-reported series and their
efforts to assess the role of endovascular technology in the man-
agement of vein graft stenosis, and would like to thank the society
for the privilege of examining this work. Thank you.
Dr Karthikeshwar Kasirajan. Thank you for your kind com-
ments and for agreeing to review the paper at the last minute, due
to a change in the discussant, and getting the discussion back to me
the next day.
As far as inflation time, we did not pick out a certain inflation
time and compare this with conventional balloon angioplasties. I
think we overcame the need to have prolonged inflation times and
high pressures by producing microincisions with the cutting bal-
loon that helped overcome hoop stress early. However, we used
the cutting balloon technology’s early recommendation to inflate
the balloon very slowly, because you want the blades to come out
perpendicular, and if you rapidly inflate the balloon, the blades may
deflect to one side, so it takes about two minutes for the balloon to
reach its maximum diameter. Hence, our average inflation time
should have been about two minutes. We did not record the
average inflation time, but I would wait for about two minutes for
the balloon to reach its profile and then I would deflate it and redo
it again—so probably four minutes, which is more time than a
conventional balloon angioplasty. I am aware that Boston Scien-
tific has recently removed the recommendation for slow inflation;
this may be based on recent coronary data. I do not believe an
inflation time of two minutes would adversely affect a peripheral
saphenous vein graft.
Regarding rewrapping the balloon. If you look at the cross-
sectional pictures, the blades are actually folded within the balloon
before inflation. I am not sure what position the blades reach on
subsequent deflation, but this did not seem to affect our ability to
withdraw the balloon. There are a few case reports on coronary
cases in which the blades did get stuck in the target lesion,
requiring an open surgical procedure. The blades are simply gluedon to the balloon surface; subsequent improvements in manufac-
turing techniques seem to have eliminated that problem.
Regarding concerns about lesions at the anastomosis, the
majority of the proximal lesions that we treated were at the
anastomosis but beyond nine months. We were a little concerned
that we might cut the suture line, but we didn’t have any problems
in the nine patients. I don’t think it is going to be a problem, if we
avoid early lesions. Probably I won’t treat the proximal lesions if I
see them within a month or two after the bypass. We may risk
cutting the suture at that point. If we cut the suture, we can simply
reinflate the balloon and open, and fix it with a patch angioplasty,
but, fortunately, we have treated most proximal lesions with no
suture line dehiscence.
Our median time for following these patients was 9 months, so
it was a little shorter than our 11-month mean follow-up. We did
not do a life table analysis because we have a total of 19 patients and
only 1 immediate failure. I thought it would make more sense if we
just looked at actual follow-up times.
Regarding other peripheral applications for the cutting bal-
loons, a few of us are collecting data on the infrapopliteal vessels
that we have treated with the cutting balloon, with an idea of
avoiding a need for stents. A dissection in the infrapopliteal vessel
using a conventional balloon angioplasty and a bail-out stent has a
very poor patency. Unfortunately, the balloon is only about 1 mm
in length and most infrapopliteal lesions are quite long, so we have
to move multiple times to be able to hit all the target lesions.
Another problem with infrapopliteal vessels is how to follow these
patients once you do your angioplasty. This may mandate repeat
angiograms for precise follow-up on target lesion data.
There is a peripheral cutting balloon that is going through
clinical trials. It is being evaluated for dialysis vein graft stenosis. I
think the balloons go up to 8 mm in diameter and should be
available probably within 6 to 9 months. I think in the future, if we
can demonstrate that cutting balloons decrease the need for rou-
tine stenting even in places like iliacs or renals, these balloons will
certainly have a major role to play. Once peripheral cutting bal-
loons are available, I will probably use cutting balloons primarily
for all peripheral angioplasties and stent only when required. I
currently primarily stent most peripheral lesions. Recent coronary
data from “Rescue III” demonstrated a six-month angiographic
restenosis rate of 19% for conventional balloons compared with
11% for cutting balloon PTA. Cutting balloons will certainly have
a major role to play in the future.
I thank the Society for the opportunity to present our data.
Dr Ronald Dalman (Palo Alto, Calif). I think as Kasi men-
tioned, Doug deserves some credit for graciously agreeing to
review this manuscript about a week in advance of the meeting
because we had to make some changes, so we appreciate that very
much, Dr Hood.
I have some questions about the technical aspects of these
procedures. The intravascular ultrasound (IVUS) that you showed,
does that specifically guide your treatment in some way? Do you
change the position of the balloon using the IVUS? Do you use it
for evidence of completion in terms of treatment? I am a little
unclear on that. You showed the example where the IVUS was
occlusive so presumably you heparinize these patients prior to
treatment or during treatment. How much heparin do you use or
for what period of time? And I guess you already discussed this a
little bit, but are you using the cutting balloons now primarily for
tibial angioplasty? What exactly is your experience with that be-
yond just the anecdotes?
Dr Kasirajan. I use IVUS on all my angioplasty patients
because an angiogram is a two-dimensional image and may not
demonstrate exactly what is happening in the other dimensions. If
I do see a significant dissection or recoil or poor stent opposition,
I re-treat these lesions. Especially in post-stent placement, wall
opposition is best evaluated with an IVUS. However, we didn’t
make any changes in the cutting balloon patients on the basis of
our IVUS images. I used IVUS in this study to evaluate the
difference between a conventional angioplasty and a cutting bal-
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microincisions made by the microtomes can be seen on the IVUS
images.
As far as heparin, I heparinize all patients when I do infrain-
guinal angioplasty—I give them all 5000 units of heparin. I don’t
check activated clotting times. I don’t base the heparin dose on the
patient’s weight. In infrainguinal angioplasty, I also give them an
intra-arterial bolus of ReoPro. However, we didn’t use ReoPro on
any of these study patients to avoid a treatment bias. I do use
ReoPro on most other infrainguinal interventions; I give them a
0.25 mg/kg body weight intra-arterial bolus of ReoPro. I don’t
continue them on a drip of ReoPro and additionally use aspirin and
recently Plavix for most peripheral interventions. The study pa-
tients were maintained on aspirin only.
As far as tibial percutaneous angioplasty, we have quite a few
patients. However, I don’t have good follow-up data on them
because our duplex lab doesn’t image infrapopliteal vessels very
well and I have not asked the patients to come back for regular
angiographic follow-up exams. Ankle brachial indexes in most of
these patients do not demonstrate a dramatic change, but we have
had quite a number of successful limb salvages. Now I don’t know
what exactly we can gather from that, but at least our angiographic
results look pretty good. I am sure most cardiologists would agree
that a good angiographic result in the periphery is considered
long-term follow-up data!
Dr Sheila Coogan (Palo Alto, Calif). Kasi, I enjoyed your
presentation, and I think that because of the fibrous nature of vein
graft stenosis I agree with the cutting balloons. I started using
them myself, but one thing is curious. In the coronary system, I
haven’t actually kept the balloon inflated for 2 to 4 minutes and
since much of this is what is done in the coronary system, it is
surprising that in the coronaries the patients would tolerate a
balloon inflation of 2 to 4 minutes. Is that standard practice in the
coronary circulation?
Dr Kasirajan. I’m not sure about the actual occlusion time.
By that, I mean you don’t leave it inflated for 2 minutes. When you
use a cutting balloon, the initial recommendation was to take it up
really slowly, so it does take about a 2-minute inflation time, not
occlusion time.
Dr Coogan. I’m just surprised the cardiologists wouldn’t find
they had ischemia that was problematic with a 2- to 4-minute
balloon inflation.
Dr Kasirajan. They probably go up faster and come down as
you have suggested. You know they are always monitoring these
patients very closely so if there are electrocardiogram changes or
angina, they would bring the balloons down immediately. I’ll let
you know what I find when I start doing my drive-by coronary
interventions!
Dr George Andros (North Hollywood, Calif). Most of us
have been around long enough to see endovascular therapies come
and go. On the one hand you want to accept them, and on the
other hand you see them go as well. I would just urge a little
respectful waiting until we have the answer on this.The question I have is, would you just tell us the difference
between your outcomes on midbody stenoses and anastomotic
stenoses, both proximal and distal, since it depends if it is proximal
or distal and whether you reverse the vein or not?
Dr Kasirajan. Fortunately we had only one failure and that
was a proximal lesion, so there was really no difference between a
proximal anastomotic, midbody, or distal anastomotic lesion.
There was a single failure so I can’t give you any statistical data on
that. There was no difference between reversed and in situ vein
bypasses. We are still continuing to follow these patients. We hope
to have 2-year data in about 30 to 40 patients, which may make
more sense, and also are thinking of comparing it with conven-
tional balloon angioplasty for which we already have plenty of data.
The one nice thing is that, if you look at all the published data on
conventional balloon angioplasty, cutting balloon certainly has
done way better. We limited ourselves to focal lesions in veins that
were at least 3.5 mm in diameter, so there may be a selection bias,
but cutting balloon angioplasty compares very favorably to open
surgery and it is much better than a conventional balloon angio-
plasty.
Dr Sam Ahn (Los Angeles, Calif). One question and com-
ment. George Andros actually is the one who told me this, but on
these vein graft restenoses, you have to inflate them for a long time
and at very high pressures to get efficacy, and so sometimes I’ll have
to take them out to 16 atmospheres and sometimes even 8 atmo-
spheres of pressure, and it requires multiple inflations, 2, 3, 4 times
for 30 seconds each and that’s a total of about 2 to 3 minutes’ total
inflation time. That is comparable to what you have done, and so
far, knock on wood, I have not had to put a stent in any of these
vein graft restenoses. This is anecdotal, but I think that until you
do a prospective randomized trial it is very hard to interpret the
results of your data.
The question I have for you, which is completely unrelated, is
this: Is the shaft size or the introducer sheath requirement larger
with these cutting balloons because of the extra space that these
blades take up, and if so is there an increased risk of access bleeding
complications?
Dr Kasirajan. No, the balloons require a standard 5 French
sheath. I’m not sure whether it will go through a 4 French. I always
use an up-and-over sheath and I always use an up-and-over 6
French Pinnacle Destination sheath. I take them all through a 6
French in case I need to place a bail-out stent.
I totally agree with you—this is our conclusion in the manu-
script. Until we have a large prospective randomized trial, we can’t
come to a valid conclusion. These are preliminary data—a feasibil-
ity study. The use of cutting balloons my help avoid the prolonged
inflation times and high pressure needed for conventional balloon
angioplasty. You produce your initial microincisions, and hence
you don’t need a high pressure to be able to get the lesion to
fracture when using the cutting balloon. Additionally, producing
your fracture along the predetermined microincisions produced by
the microtomes eliminates the risk of an uncontrolled dissection.
That is what we are hoping to achieve and have, in our limited
series, by using the cutting balloon.
